Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial

The lancet oncology, 2017-03, Vol.18 (3), p.357-370 [Peer Reviewed Journal]

The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license ;2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license ;Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license. Published by Elsevier Ltd.. All rights reserved. ;Copyright Elsevier Limited Mar 01, 2017 ;2017. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license 2017 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(17)30043-8 ;PMID: 28163000 ;CODEN: LANCAO

Full text available